Physician profile
Manu Joseph
NPI 1902006406
$2,716.06
in general payments reported to CMS, 2019-2025
29 companies · $17.86 in 2025
The $17.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $741 · 2021: $31.03 · 2023: $18.76 · 2025: $17.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.21 | 2019-2021 | |
| Amgen INC. | $267.55 | 2019-2020 | |
| Lilly USA, LLC | $217.06 | 2019-2020 | |
| Allergan, INC. | $174.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $173.44 | 2019-2020 | |
| Pfizer INC. | $149.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $149.73 | 2019-2020 | |
| Novo Nordisk INC | $123.90 | 2019-2020 | |
| Amarin Pharma, INC. | $108.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $73.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.48 | 2019 | |
| Seqirus USA INC | $70.50 | 2019-2020 | |
| Abbvie INC. | $62.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $52.28 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.84 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.30 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $35.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.44 | 2019 | |
| Boston Scientific Corporation | $18.76 | 2023 | Watchman Access System |
| Lundbeck LLC | $17.86 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.21 | 2020 | |
| Genentech USA, INC. | $16.69 | 2020 | |
| Sanofi Pasteur INC. | $15.24 | 2020 | |
| Ibsa Pharma INC. | $12.69 | 2019 | |
| Eisai INC. | $11.90 | 2019 | |
| Cardiovascular Systems INC. | $7.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manu Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.